2021
Loss of crossbridge inhibition drives pathological cardiac hypertrophy in patients harboring the TPM1 E192K mutation
Sewanan LR, Park J, Rynkiewicz MJ, Racca AW, Papoutsidakis N, Schwan J, Jacoby DL, Moore JR, Lehman W, Qyang Y, Campbell SG. Loss of crossbridge inhibition drives pathological cardiac hypertrophy in patients harboring the TPM1 E192K mutation. The Journal Of General Physiology 2021, 153: e202012640. PMID: 34319370, PMCID: PMC8321830, DOI: 10.1085/jgp.202012640.Peer-Reviewed Original ResearchConceptsHypertrophic cardiomyopathyHeart tissueCellular hypertrophyEngineered Heart TissuePathological cardiac hypertrophyThin filament mutationsMavacamten treatmentDiastolic dysfunctionDisease featuresHypertrophic effectCardiac hypertrophyContractile differencesHypertrophyFundamental disease mechanismsCrossbridge activityInherited disorderOverall Ca2Uncertain significancePatient phenotypesDisease mechanismsLow Ca2PatientsK mutationMavacamtenTissue
2016
Implantable tissue-engineered blood vessels from human induced pluripotent stem cells
Gui L, Dash BC, Luo J, Qin L, Zhao L, Yamamoto K, Hashimoto T, Wu H, Dardik A, Tellides G, Niklason LE, Qyang Y. Implantable tissue-engineered blood vessels from human induced pluripotent stem cells. Biomaterials 2016, 102: 120-129. PMID: 27336184, PMCID: PMC4939127, DOI: 10.1016/j.biomaterials.2016.06.010.Peer-Reviewed Original ResearchConceptsVascular smooth muscle cellsVascular diseaseBlood vesselsAlpha-smooth muscle actinSmooth muscle myosin heavy chainActive vascular remodelingSmooth muscle cellsMuscle myosin heavy chainTissue-engineered blood vesselsStem cellsAbundant collagenous matrixPluripotent stem cellsInterposition graftAllogeneic graftsVascular remodelingΑ-SMANude ratsMuscle actinMyosin heavy chainClinical useMuscle cellsFunctional vascular smooth muscle cellsPatientsFunctional tissue-engineered blood vesselGraft